How Daiichi Sankyo aims to become a top five oncology player by 2035

▤ Summary

Daiichi Sankyo is building a long-term oncology strategy around its DXd antibody-drug conjugate platform. The company wants to become a top-five global oncology player by 2035 and expects Enhertu, Datroway, and several late-stage pipeline assets to drive most of that growth. It is also investing in next-generation payloads, tumor-selective antibodies, multi-specific antibodies, targeted protein degraders, and siRNA programs to extend beyond its current ADC wave. Daiichi Sankyo plans to spend heavily on R&D while also using AI-driven cost optimization to improve efficiency and free staff from routine work.

▦ Linked Companies